Concurrent 0 10 0 10 O
enrollment 11 21 11 21 O
in 22 24 22 24 O
another 25 32 25 32 O
therapeutic 33 44 33 44 O
investigational 45 60 45 60 O
study 61 66 61 66 O
or 67 69 67 69 O
prior 70 75 70 75 B-treatment
therapy 76 83 76 83 I-treatment
with 84 88 84 88 O
ibrutinib 89 98 89 98 B-treatment
or 99 101 99 101 O
other 102 107 102 107 O
BTK 108 111 108 111 B-treatment
inhibitors 112 122 112 122 I-treatment

Pathologically 0 14 123 137 O
confirmed 15 24 138 147 O
MCL 25 28 148 151 B-cancer
( 29 30 152 153 O
in 30 32 153 155 O
tumor 33 38 156 161 O
tissue 39 45 162 168 O
) 45 46 168 169 O
, 46 47 169 170 O
with 48 52 171 175 O
documentation 53 66 176 189 O
of 67 69 190 192 O
either 70 76 193 199 O
overexpression 77 91 200 214 O
of 92 94 215 217 O
cyclin 95 101 218 224 O
D1 102 104 225 227 O
in 105 107 228 230 O
association 108 119 231 242 O
with 120 124 243 247 O
other 125 130 248 253 O
relevant 131 139 254 262 O
markers 140 147 263 270 O
( 148 149 271 272 O
eg 149 151 272 274 O
, 151 152 274 275 O
CD19 153 157 276 280 O
, 157 158 280 281 O
CD20 159 163 282 286 O
, 163 164 286 287 O
PAX5 165 169 288 292 O
, 169 170 292 293 O
CD5 171 174 294 297 O
) 174 175 297 298 O
or 176 178 299 301 O
evidence 179 187 302 310 O
of 188 190 311 313 O
t(11;14 191 198 314 321 O
) 198 199 321 322 O
as 200 202 323 325 O
assessed 203 211 326 334 O
by 212 214 335 337 O
cytogenetics 215 227 338 350 O
, 227 228 350 351 O
fluorescent 229 240 352 363 B-treatment
in 241 243 364 366 I-treatment
situ 244 248 367 371 I-treatment
hybridization 249 262 372 385 I-treatment
( 263 264 386 387 I-treatment
FISH 264 268 387 391 I-treatment
) 268 269 391 392 I-treatment
, 269 270 392 393 O
or 271 273 394 396 O
polymerase 274 284 397 407 B-treatment
chain 285 290 408 413 I-treatment
reaction 291 299 414 422 I-treatment
( 300 301 423 424 I-treatment
PCR 301 304 424 427 I-treatment
) 304 305 427 428 I-treatment

